Literature DB >> 12512918

Clinical significance of nm23 expression and chromosome 17 numerical aberrations in primary gastric cancer.

Ryusuke Terada1, Toru Yasutake, Shirou Nakamura, Takashi Hisamatsu, Terumitsu Sawai, Hiroyuki Yamaguchi, Tohru Nakagoe, Hiroyoshi Ayabe, Yutaka Tagawa.   

Abstract

The metastasis suppressor gene nm23 located on chromosome 17 might be one of the targets in deletions of chromosome 17. In this study, we analyzed the expression of nm23 and chromosome 17 aberrations in gastric cancer and assessed their clinicopathological and prognostic significance. In 103 gastric cancer patients, we examined nm23 expression by immunohistochemistry and detected chromosome 17 aberrations by fluorescence in situ hybridization. There was a significant difference in the expression of nm23 among differentiated histologic types (well > moderately > poorly) (p < 0.01). Negative expression of nm23 correlated with depth of invasion (p < 0.01), lymph node metastasis (p < 0.05), lymphatic invasion (p < 0.05), venous invasion (p < 0.05), poor prognosis (p < 0.05), and chromosome 17 loss (p < 0.05). Chromosome 17 aberrations broadly correlated with clinicopathological variables and were associated with poor prognosis (p < 0.05). Univariate analyses identified nm23 (p < 0.05), chromosome 17 aberrations (p < 0.05), tumor size (p < 0.01), depth of invasion (p < 0.0001), lymph node metastasis (P < 0.001), hepatic metastasis (p < 0.01), peritoneal dissemination (p < 0.01), and lymphatic invasion (p < 0.01) as significant prognostic factors. Multivariate analysis showed that expression of nm23 and chromosome 17 aberrations were not independent prognostic indicators. Our results indicate that negative expression of nm23 and chromosome 17 numerical aberrations correlate with tumor progression and poor prognosis but are not independent prognostic indicators.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12512918     DOI: 10.1385/MO:19:4:239

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  28 in total

1.  Analysis of chromosome 17p13 (p53 locus) alterations in gastric carcinoma cells by dual-color fluorescence in situ hybridization.

Authors:  M Kobayashi; A Kawashima; M Mai; A Ooi
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

2.  Altered expression of NM23, a gene associated with low tumor metastatic potential, during adenovirus 2 Ela inhibition of experimental metastasis.

Authors:  P S Steeg; G Bevilacqua; R Pozzatti; L A Liotta; M E Sobel
Journal:  Cancer Res       Date:  1988-11-15       Impact factor: 12.701

3.  Expression of nm23 protein in pulmonary adenocarcinomas: inverse 1orrelation to tumor progression.

Authors:  Y Kawakubo; Y Sato; T Koh; H Kono; T Kameya
Journal:  Lung Cancer       Date:  1997-05       Impact factor: 5.705

4.  Survival and acquired genetic alterations in colorectal cancer.

Authors:  P Laurent-Puig; S Olschwang; O Delattre; Y Remvikos; B Asselain; T Melot; P Validire; M Muleris; J Girodet; R J Salmon
Journal:  Gastroenterology       Date:  1992-04       Impact factor: 22.682

5.  Association of low nm23 RNA levels in human primary infiltrating ductal breast carcinomas with lymph node involvement and other histopathological indicators of high metastatic potential.

Authors:  G Bevilacqua; M E Sobel; L A Liotta; P S Steeg
Journal:  Cancer Res       Date:  1989-09-15       Impact factor: 12.701

6.  Expression of nm23 in gastric carcinoma: association with tumor progression and poor prognosis.

Authors:  W Müller; A Schneiders; G Hommel; H E Gabbert
Journal:  Cancer       Date:  1998-12-15       Impact factor: 6.860

7.  Clinical and pathological significance of numerical aberrations of chromosomes 11 and 17 in colorectal neoplasms.

Authors:  Y Tagawa; T Yasutake; T Sawai; A Nanashima; M Jibiki; M Morinaga; F Akama; T Nakagoe; H Ayabe
Journal:  Clin Cancer Res       Date:  1997-09       Impact factor: 12.531

8.  Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex steroid receptor expression.

Authors:  M Mandai; I Konishi; M Koshiyama; T Mori; S Arao; H Tashiro; H Okamura; H Nomura; H Hiai; M Fukumoto
Journal:  Cancer Res       Date:  1994-04-01       Impact factor: 12.701

9.  Nm23 expression in endometrial and cervical cancer: inverse correlation with lymph node involvement and myometrial invasion.

Authors:  M Marone; G Scambia; G Ferrandina; C Giannitelli; P Benedetti-Panici; S Iacovella; A Leone; S Mancuso
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

10.  Reduced expression of nm23 is associated with metastasis of human gastric carcinomas.

Authors:  H Nakayama; W Yasui; H Yokozaki; E Tahara
Journal:  Jpn J Cancer Res       Date:  1993-02
View more
  4 in total

1.  Chromosome 8 numerical aberrations in stage II invasive ductal carcinoma: correlation with patient outcome and poor prognosis.

Authors:  Yutaka Tagawa; Toru Yasutake; Yasushi Ikuta; Tadayuki Oka; Ryusuke Terada
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

2.  Prognostic value of nm23 in gastrointestinal stromal tumors.

Authors:  Ozkan Kanat; Saduman Adim; Turkkan Evrensel; Omer Yerci; Bulent Ediz; Ender Kurt; Mutlu Demiray; Guzin Gonullu; Murat Arslan; Osman Manavoglu
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

Review 3.  Meta-Analysis of the Relationship between NM23 Expression to Gastric Cancer Risk and Clinical Features.

Authors:  Min Fang; Yifeng Tao; Zhimin Liu; Hao Huang; Min Lao; Lingsha Huang; Bo Zhu
Journal:  Biomed Res Int       Date:  2017-03-16       Impact factor: 3.411

Review 4.  Prognostic Value of NME1 (NM23-H1) in Patients with Digestive System Neoplasms: A Systematic Review and Meta-Analysis.

Authors:  Wei Han; Chun-Tao Shi; Fei-Yun Cao; Fang Cao; Min-Bin Chen; Rong-Zhu Lu; Hua-Bing Wang; Min Yu; Da-Wei He; Qing-Hua Wang; Jie-Feng Wang; Xuan-Xuan Xu; Hou-Zhong Ding
Journal:  PLoS One       Date:  2016-08-12       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.